TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03633149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer tablet-delivered C4H
Description: Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-delivered C4H
Description: Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
Study: NCT02767492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioD Restore
Description: Investigational product, BioD Restore, will be injected into the articular space of the knee.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
Study: NCT01305889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem solving therapy
Description: 12 weeks of weekly 45 minute sessions of problem solving therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
Study: NCT02280616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose budesonide tablet
Description: 1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose budesonide tablet
Description: 2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose budesonide suspension
Description: placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet twice daily AND 5ml placebo suspension twice daily
Study: NCT01765777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Study: NCT03275675

Intervention type: DRUG
Intervention: Oral anticancer medications
Description: All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
Study: NCT02691936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractionated vaginal laser
Description: Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogens, Conjugated (USP)
Description: Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
Study: NCT02120820

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory environment (MSE)
Description: Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory environment (MSE)
Description: Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy (MT)
Description: A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy (MT)
Description: A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy in multisensory environment (MT-MSE)
Description: Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
Study: NCT03431662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ellipse IM HTO Nail
Description: A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
Study: NCT01378481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo fractionated stereotactic radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03431662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TomoFix
Description: A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
Study: NCT02010281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS of prefrontal or motor cortex
Description: description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS of prefrontal or motor cortex
Description: description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS of prefrontal or motor cortex
Description: description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
Study: NCT01437917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% amylose bread
Description: 20% amylose bread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10% amylose bread
Description: 10% amylose bread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrates
Description: 50g of carbohydrates ingested with 400 ml of water
Study: NCT00279617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: open label levetricetam
Study: NCT01378481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo neurosurgery
Study: NCT04617665

Intervention type: OTHER
Group type: OTHER
Intervention: One-handed mask ventilation
Description: Using one-handed mask ventilation techniques during induction of general anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: Two-handed mask ventilation
Description: Using two-handed mask ventilation techniques during induction of general anesthesia
Study: NCT04018261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated T-Lymphocytes
Description: Activated T-Lymphocytes will be infused intravenously in a single-dose
Study: NCT03081559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Divas
Description: Peer-based counseling to improve medication adherence and engagement in care
Study: NCT04021147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus action observation
Description: Orofacial exercise plus action observation (video) of the same exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus motor imagery
Description: Orofacial exercise plus motor imagery of the same exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus visual mirror feedback
Description: Exercise plus visual mirror feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Orofacial exercises
Study: NCT04365738

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
Study: NCT03761407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GRT0151Y
Description: 100 mg capsule (1 x 100 mg capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg GRT0151Y
Description: 125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg GRT0151Y
Description: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225 mg GRT0151Y
Description: Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo capsules using the same dosing regimen as defined in the treatment groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo capsules using the same dosing regimen as defined in the treatment groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo capsules using the same dosing regimen as defined in the treatment groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
Study: NCT02722122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR DNase™
Study: NCT00033462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study: NCT03692975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
Study: NCT00951509

Intervention type: OTHER
Intervention: Power Mobility Road Test (PMRT)
Description: All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.

Intervention type: OTHER
Intervention: Power Mobility Road Test (PMRT)
Description: All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
Study: NCT03692975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Evaluation
Description: Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
Study: NCT00951509

Intervention type: OTHER
Intervention: Power Mobility Road Test (PMRT)
Description: All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
Study: NCT03692975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Evaluation
Description: Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
Study: NCT03911986

Intervention type: DEVICE
Group type: OTHER
Intervention: R Test 4 External Loop Recorder
Description: The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.

Intervention type: DEVICE
Group type: OTHER
Intervention: R Test 4 External Loop Recorder
Description: The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
Study: NCT00742872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride Citrate
Description: One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
Study: NCT01783600

Intervention type: DEVICE
Group type: OTHER
Intervention: NanoCross .014 balloon catheter
Study: NCT04229602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg
Description: A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFEXOR® XR
Description: EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
Study: NCT03166540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cup of espresso coffee
Description: Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cup of espresso coffee
Description: Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cup of espresso coffee
Description: Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cocoa-based products containing coffee
Description: Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
Study: NCT04884113

Intervention type: DEVICE
Intervention: Motorized Spiral enteroscopy
Description: Small-bowel enteroscopy for diagnosis and intervention
Study: NCT03177434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycols (PEG) 3350
Description: Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Oral Product
Description: Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
Study: NCT01312233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care
Description: Participants allocated to all three treatment groups receive medical care over a 12-week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self-management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti-inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual Care
Description: Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity-low amplitude or low velocity-variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shared Care
Description: Participants allocated to Shared Care receive co-managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
Study: NCT03671564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.
Study: NCT00805870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (omega-3-acid ethyl esters)
Description: Lovaza, 3 grams per day for 65 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Germ Oil
Description: Wheat germ oil, 3 grams/day for 65 days
Study: NCT04869319

Intervention type: BEHAVIORAL
Intervention: MyChart message
Description: Message subjects through MyChart to follow-up with their provider to schedule a follow up HbA1C test.
Study: NCT02573831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
Study: NCT03281187

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasotestt 5 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasotestt 5 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgel 50 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgel 50 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasotestt Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasotestt Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Androgel Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgel Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
Study: NCT03633799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VeraCept
Description: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
Study: NCT00033462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies